Health
Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months
Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel experienced a statistically significant 51 percent reduction in the risk of death compared to those who initiated on darolutamide without docetaxel through 24-months of follow-up (hazard ratio [HR] 0.49; 95% confidence interval [CI], 0.30–0.83; P=0.007). These findings reflecting patients treated in r
About this update from Johnson & Johnson
[{"type":"text","content":"First ever head-to-head analysis compares overall survival outcomes of ERLEADA® versus darolutamide ","length":99,"tagName":"p"},{"type":"text","content":"Retrospective study reinforces real-world efficacy of ERLEADA® for patients with mCSPC","length":86,"tagName":"p"},{"type":"text","content":"HORSHAM, Pa., Feb. 2, 2026 /PRNewswire/ -- Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel experienced a statistically significant 51 percent reduction in the risk of death compared to those who initiated on darolutamide without docetaxel through 24-months of follow-up (hazard ratio [HR] 0.49; 95% confidence interval [CI], 0.30–0.83; P=0.007). These findings reflecting patients treated in routine clinical practice are being presented at the 36th Annual International Prostate Cancer Update on February 2, where it was selected as a top abstract (Abstract #6).","length":722,"tagName":"p"},{"type":"image","alt":"Johnson & Johnson (PRNewsfoto/Johnson & Johnson)","displaySize":"","headline":null,"caption":"Johnson & Johnson (PRNewsfoto/Johnson & Johnson)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":38,"url":"https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l1P3ZFYFL52xeQr0zq6rKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY3O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721","width":400,"height":38}},"href":"https://mma.prnewswire.com/media/2343818/Johnson_and_Johnson_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Designed to meet rigorous FDA guidance and robust methodological framework on real-world evidence, this study included a pre-specified protocol, pre-specified primary endpoint of overall survival (OS), power calculation, and propensity score matching through inverse probability of treatment weighting (IPTW).1,2,3 Together, these methodological safeguards deliver robust, reproducible insights that inform real-world treatment decisions. The retrospective study identified mCSPC patients who initiated ERLEADA® or darolutamide without docetaxel between August 2022 and June 2025. There were 1,460 ERL...